Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Aug 1.

Published in final edited form as: Pharmacogenet Genomics. 2017 Aug;27(8):285–293. doi: 10.1097/FPC.0000000000000289

Table 6. Cardiovascular events by HCAR2 genotype in AIM-HIGH participants.

SNP	Genotype	Statin + placebo (n=1,020)	HR	95% CI	p-value	Statin + ER Niacin (n=1,047)	HR	95% CI	p-value

p.R311C	Arg/Arg	121 (17.3%)	0.87	0.65, 1.17	0.38	114 (15.7%)	0.99	0.74, 1.32	0.94
	Arg/Cys	41 (14.6%)				49 (17.3%)
	Cys/Cys	5 (13.5%)				2 (7.1%)

p.M317I	Met/Met	69 (17.8%)	0.91	0.73, 1.14	0.42	65 (16.8%)	1.06	0.85, 1.32	0.61
	Met/Ile	71 (14.3%)				72 (14.5%)
	Ile/Ile	24 (14.4%)				34 (20.7%)

HR= hazard ratio from Cox regression adjusted for age, sex, race, BMI